Name of journal: *World Journal of Transplantation*

ESPS Manuscript NO: 10594

Columns: REVIEW

**Female gender in the setting of liver transplantation**

Rodriguez-Castro KI *et al.* Female gender and liver transplantation

Kryssia Isabel Rodriguez-Castro, Eleonora De Martin, Martina Gambato, Silvia Lazzaro, Erica Villa, Patrizia Burra

**Kryssia Isabel Rodriguez-Castro, Eleonora De Martin, Martina Gambato, Silvia Lazzaro, Patrizia Burra,** Multivisceral Transplant Unit, Deparment of Surgery, Oncology and Gastroenterology, Padua University Hospital, 35128 Padua, Italy

**Erica Villa,** Department of Gastroenterology, Azienda Ospedaliero-Universitaria and University of Modena and Reggio Emilia, 41124 Modena, Italy

**Author contributions:** Rodriguez-Castro KI contributed to the conception, design, and performance of the research, drafting of the manuscript, approval of the final version; De Martin E contributed to the conception, design, and performance of the research, drafting of the manuscript, approval of the final version; Gambato M contributed to the critical revision of the manuscript, approval of the final version; Lazzaro S critically revised the manuscript, approval of the final version; Villa E contributed to the conception and design of the research, critical revision of the manuscript, approval of the final version; Burra P contributed to the conception and design of the research, critical revision of the manuscript, approval of the final version.

**Correspondence to:**  **Patrizia Burra, MD, PhD,** Multivisceral Transplant Unit, Department of Surgery, Oncology and Gastroenterology, Padua University Hospital, Via Giustiniani 2, 35128 Padua, Italy. burra@unipd.it

**Telephone:** +39-049-8212892 **Fax:** +39-049-8218727

**Received:** April 8, 2014 **Revised:** May 27, 2014

**Accepted:** July 15, 2014

**Published online:**

**Abstract**

The evolution of liver diseases to end-stage liver disease or to acute hepatic failure, the evaluation process for liver transplantation, the organ allocation decision-making, as well as the post-transplant outcomes are different between female and male genders. Women’s access to liver transplantation is hampered by the use of model for end-stage liver disease (MELD) score, in which creatinine values exert a systematic bias against women due to their lower values even in the presence of variable degrees of renal dysfunction. Furthermore, even when correcting MELD score for gender-appropriate creatinine determination, a quantifiable uneven access to transplant prevails, demonstrating that other factors are also involved. While some of the differences can be explained from the epidemiological point of view, hormonal status plays an important role. Moreover, the pre-menopausal stage and the post-menopausal stage imply profound differences in a woman’s physiology, including not only the passage from the fertile age to the non-fertile stage, but also the loss of the potentially protective role of estrogens in delaying liver fibrosis progression, amongst others. With menopause, the tendency to gain weight may contribute to the development of or worsening of pre-existing metabolic syndrome. As an increasing number of patients are transplanted for non-alcoholic steatohepatitis, and as the average age at transplant increases, clinicians must be prepared for the management of this particular condition, especially in post-menopausal women, who are at a particular risk of developing metabolic complications after menopause.

© 2014 Baishideng Publishing Group Inc. All rights reserved.

**Key words:** Liver transplantation; Female gender; Estrogens; Model for end-stage liver disease score; Creatinine; Gender donor-recipient match

**Core tip:** Gender differences play an important role in liver diseases, their evolution and outcome, and in liver transplantation, not only in terms of access to this resource, but also in terms of graft survival, metabolic aspects, and quality of life after liver transplantation. Not only gender differences, are important, however, but clearly the different hormonal status throughout a woman’s lifetime determines many aspects not only regarding fertility and sexual issues such as pregnancy, but also metabolic complications. Notwithstanding this, decision-making algorithms regarding indications, risk factors, and outcomes after transplant do not yet incorporate many of these concepts that affect the clinical practice.

Rodriguez-Castro KI, De Martin E, Gambato M, Lazzaro S, Villa E, Burra P. Female gender in the setting of liver transplantation. *World J Transplant* 2014; In press

**INTRODUCTION**

It is ever clearer that gender differences play an important role in liver diseases, their evolution and outcome, and in liver transplantation (LT), not only in terms of access to this resource, but also in terms of graft survival, metabolic aspects, and quality of life after LT. Nevertheless, proposed measures for correcting the systematic bias disadvantaging women’s access to LT, and the gender variable itself, are not yet fully incorporated into decision-making algorithms regarding evaluation of indications, risk factors, and outcomes in LT. The present review, therefore aims at highlighting gender differences in diseases that lead to LT, access to LT, and outcomes after transplant.

### GENDER DISPARITY IN ACCESS TO LIVER TRANSPLANTATION

***Sociodemographic determinants***

Access to a life-saving resource such as LT has unfortunately been hampered for ethnic minorities, women, and patients of low socioeconomic status or inadequate insurance coverage; in a study analyzing health care inequities that prevent patients with end-stage liver disease from being evaluated and waitlisted for LT, patients were less likely to undergo evaluation, waitlisting and transplantation if they were women, black and lacked commercial insurance (*P* < 0.001 each)[1] .

This disparity of access to LT probably owes to several factors, including body and organ size considerations, differences in the etiology of the underlying liver disease, and limits of the model for end-stage liver disease (MELD) score, especially regarding creatinine levels[2].

***MELD, MELD-related issues and non-MELD determinants of access to LT***

In the pre-MELD era, a study from the Organ Procurement and Transplantation Network (OPNT) showed that female sex was significantly correlated with longer stay on the liver transplant waiting list and also with the risk of dying before LT[3]. Unequal access to LT for women was unfortunately perpetuated upon implementation of the MELD score for organ allocation, however. In a study based on UNOS data comparing pre- and post-MELD cohorts, women were more likely than men to die or become too sick for LT post-MELD (23.7% *vs* 21.4%; odds ratio (OR), 1.30; *P* = 0.003) *vs* pre-MELD (22.4% *vs* 21.9%; OR, 1.08; *P* = 0.37). Similarly, women were less likely than men to receive a liver transplant within 3 years both pre-MELD (64.8% *vs* 67.6%; OR, 0.80; *P* = 0.002) and post-MELD (39.9% *vs* 48.7%; OR, 0.70; *P* < 0.001)[4].Actually, organ allocation based on MELD sore has further increased gender disparity, as waiting list mortality risk has risen, particularly for MELD scores > 15[5]. In fact, female gender, together with primary non-function, fulminant hepatic failure, blood group O, CTP ≥ 11 and MELD score ≥ 20 have been found to be predictors of waiting list mortality[6].

A systematic bias against women, resulting in part from the use of creatinine as a measure of renal function, has been identified in MELD-based liver allocation. Women’s lesser body (and muscular) mass determines lower creatinine levels, one of the most important determinants of MELD score; due to the employment of creatinine instead of weight-adjusted glomerular filtration rate (GFR), the degree of renal dysfunction is likely in women is likely underestimated. Thus, MELD scores will be lower in women than in men with the same degree of renal compromise, which inevitably leads to a decreased access for women to LT[2]. Moreover, attempts at correcting creatinine-induced MELD bias against women by including estimated GFR have not improved discrimination for 3-mo mortality after enrolment for LT[7]. Likewise, the accuracy of MELD score in predicting 3- and 6-mo mortality in female LT candidates did not improve with the employment of the Modification of Diet in Renal Disease (MDRD) formula[8]. Providing that renal function assessment was adequately corrected for gender, a negative bias against women would still remain, since women are more likely than men to suffer from autoimmune liver diseases, including primary biliary cirrhosis, which are less likely than hepatitis C (HCV) to lead to kidney dysfunction and higher MELD scores[2].

Moreover, aside from the inaccuracy of MELD score in terms of renal dysfunction assessment in female patients, it is well known that patients with certain pathological conditions are poorly served by this score, including refractory ascites, refractory encephalopathy, recurrent cholangitis, and intractable pruritus in cholestatic diseases[9], the latter of which encompass mainly women[10–12]. Nevertheless, some of these conditions constitute symptom-based MELD exceptions and are awarded extra MELD points[13].

On the other hand, standard exclusions to MELD, which are more regularly applied, include the presence of hepatocellular carcinoma (HCC)[14–18]. , which is more common in men, further increasing the disparity of access to LT. After the implementation of the Milan Criteria[14], the number of LTs for HCC has increased worldwide and currently in Europe about 27% of all LT patients have HCC with countries peaking over 40%[19]. While exception points have greatly improved access to transplantation for HCC patients[20], recent studies suggest that the current point scheme inadvertently prioritizes HCC over patients without HCC diagnosis (non-HCC) by overestimating the presumed risk of tumor progression[21,22]. Even more vexing is the observation that even for equal MELD scores, women are at a disadvantage with respect to men in terms to LT access, suggesting that other factors must play a role in the gender disparity documented for LT rates[7,23].

### GENDER DIFFERENCES IN INDICATIONS FOR LT

According to the OPTN records for LT performed in the US between January 1, 1988 until December 31, 2013[24], a search for gender by diagnosis outlines several significant gender differences: significantly more women than men underwent LT for Wilson disease (410/47608 *vs* 326/78534, *P* < 0.0001), primary biliary cirrhosis (4796/47608 *vs* 809/78534, *P* < 0.0001), drug-induced acute hepatic necrosis (748/47608 *vs* 295/78534, *P* < 0.0001), Budd Chiari syndrome 441/47608 *vs* 233/78534), autoimmune cirrhosis 3025/47608 *vs* 959/78534, *P* < 0.0001), cryptogenic cirrhosis (4245/47608 *vs* 5009/78534, *P* < 0.0001), and non-alcoholic steatohepatitis (NASH) (1673/47608 *vs* 1875/78534, *P* < 0.0001).

On the contrary, significantly more men underwent LT for alcoholic cirrhosis (11195/78534 *vs* 3227/47608, *P* < 0.0001), alcoholic cirrhosis with HCV (4938/78534 *vs* 888/47608, *P* < 0.0001), HCC (2768/78534 *vs* 899/47608, *P* < 0.0001 ), HCC and cirrhosis (77555/78534 *vs* 2099/47608, *P* < 0.0001), HBsAg+ Hepatitis B (2778/78534 *vs* 651/47608, *P* < 0.0001), and HCV (18187/78534 *vs* 8135/47608, *P* < 0.0001)[24].

***Viral hepatitis***

Several studies have demonstrated a differential effect of gender on the outcomes of patients infected with HCV, showing that in female patients, the natural history of HCV virus infection tends to be characterized by slower rates of progression to advanced liver disease, with better response rates to antiviral therapy[25–28]. Moreover, overall lower death rates for HCV-related liver disease as well as lower rates of HCC are observed in female patients[29].

Regarding menopausal course of HCV-related liver disease, however, recent studies have reported that the reduced estrogen levels that characterize this state may determine the accelerated progression to fibrosis and higher rates of no response to antiviral therapy observed in this subpopulation, especially in genotype 1 HCV-infected patients[30–32].; a statistically significant increase of tumor necrosis factor-α and interleukin-6 occur in menopause, and these proinflammatory cytokines have been associated to increased resistance to interferon-based therapy[33]. A higher SVR rate with Peg-IFNα-2b plus ribavirin vs IFNα-2a plus ribavirin has been documented in menopausal women, which likely corresponds the former’s pharmacokinetic properties that allow the drug to reach visceral fat and oppose the increased cytokine production and enhanced inflammatory status in menopause[34].

Regarding hepatitis B (HBV), although significantly more men than women are transplanted for chronic HBV, LT for fulminant HBV is significantly more frequent in women[35]. As well, hepatitis E virus (HEV) is unfortunately associated with disproportionately high rates of fulminant hepatitis in pregnant women, particularly during the third trimester, with case-fatality rates in epidemics ranging from 0.2%-4% in the general population, vs 10%-25% in the pregnant population[36–38], possibly reflecting hormonal changes that increase susceptibility to a more aggressive course[39].

***Non-alcoholic steatohepatitis***

NASH has increased in frequency as indication for LT[40–42], and is bound to become one of the principal indications in many Western countries, with the increasing worldwide prevalence of this entity[43], and with the advent of new-acting direct antiviral agents, which will probably contribute to decreasing the percentage of HCV patients who necessitate LT.

In a study analyzing characteristics of patients referred for LT evaluation due to NASH (*n* = 71) from 1998 to 2008, and compared to the non-NASH possible candidates (*n* = 472)[44], it was found that patients with NASH were older (58.7 *vs* 52.5 year, *P* < 0.0001) and more likely of female gender (50.7% *vs* 32.1%, *P* = 0.003). As expected, NASH patients were more likely to suffer from diabetes, hypertension, obesity, and cardiac disease (*P* < 0.05). Moreover, for paired MELD scores, NASH was associated with similar bilirubin levels (2.34 *vs* 3.16 mg/dL; *P* = 0.11), but significantly increased creatinine values (1.26 mg/dL *vs* 0.98 md/dL; *P* = 0.0018) and lower international normalized ratio (INR) values (1.14 *vs* 1.27; *P* = 0.04), in contrast with LT candidates without NASH, respectively. This suggests that NASH is associated with renal dysfunction, which is translated into greater priority, as established by the MELD calculus.

Thus, MELD score in this setting might not truly reflect liver dysfunction, but could be more directly related to features of the metabolic syndrome, including microvascular renal damage associated with diabetes and hypertension. Therefore, the disadvantage posed to women by creatinine’s weight in the MELD calculus formula might be outweighed in the future, with increasing number of patients being transplanted for NASH, most of them being of female gender. However, the present state of the matter is yet far from this scenario, as only 5%-8% of LT are currently performed for this indication, and the time needed for MELD’s disparity to be counterbalanced by this theoretical female gender benefit is expectedly long[2].

Putting together all these data is especially concerning, since women are generally more likely to have GFR < 60 mL/min per 1.73 m2 previous to LT with respect to men, and the presence of this factor (OR 3.28, *P* ≤ 0.001), aside from female gender (OR 2.96, *P* < 0.001) and age (OR 1.09, *P* < 0.001), has been demonstrated to be independently predictive of stage ≥ 3 chronic kidney disease (CKD) at 1 year post-LT[45]. In addition, this same study demonstrated that female gender (OR 2.52, *P* = 0.004), age (OR 1.05, *P* = 0.003) and NASH (OR 2.95, *P* = 0.039) were independently predictive of ≥ stage 3 CKD at 5 years post-LT.

Considering, that NASH LT recipients are more frequently women, that women’s renal dysfunction is not adequately accounted for by creatinine measurement and thus not well served by MELD score, together with the fact that women are more likely to have compromised renal function prior to transplant, and that this variable predicts advanced CKD after LT, it becomes clear that this population stands a particular risk and should be addressed more carefully.

***Autoimmune hepatitis***

Differences in sex-hormone (estrogen and androgen) modulation of the immune system may be responsible for gender variations observed in autoimmune disorders; women have a significantly higher number of CD4+T lymphocytes and a higher CD4+/CD8+ ratio than men[46], secretion of interferon-γ and interleukin 10 are enhanced after the addition of estrogen in T-cell clones isolated from women[47], while androgens have been demonstrated to inhibit the secretion of IFN-γ, IL-4, and IL-5 in murine T cells[48].

Autoimmune hepatitis (AIH), characterized by progressive inflammatory destruction of the liver parenchyma associated with the presence of circulating autoantibodies, hypergammaglobulinemia and interface hepatitis on liver biopsy, is strongly preponderant in females (female/male ratio is 3.6/1)[49]. Although corticosteroid treatment tends to achieve transaminase normalization more frequently in female patients[50], women appear to have worse long-term survival than men[51].

***Primary biliary cirrhosis***

Primary biliary cirrhosis, a chronic cholestatic liver disease characterized by immune-mediated inflammatory destruction of the small intrahepatic bile ducts and fibrosis, affects predominantly women with respect to men, with incidence rates ranging from 3:1 to 22:1, with an average incidence rate in women of 10:1[52]. Gender differences also characterize the evolution of the disease: diagnosis of PBC is usually established at a younger age in women (51 years in women *vs* 62 years in men)[53]. Women are more likely to be symptomatic, and experience pruritus as a single symptom more often than males, while jaundice, jaundice with pruritus, and upper gastrointestinal bleeding are more frequently manifested in men[54]. Some symptoms such as severe daytime somnolence and depressive symptoms seem to affect men and women in an equal proportion, while autonomic symptoms seem to be more severe in women[55,56]. The presence of concomitant autoimmune disorders such as Sicca syndrome, overlap syndrome, and autoimmune hepatitis, also determining a more aggressive course and generally poorer response to therapy, is more frequent in women, especially in those of Hispanic origin, as has been recently demonstrated in a US cross-sectional study[57]. Development of hepatocellular carcinoma, however, seems to be more frequent in men[58]. Although PBC entails a high risk of postmenopausal osteoporosis, it seems to be more associated with the severity of chronic liver disease, rather than specifically the PBC etiology[59], and a recent Cochrane database systematic review reported that in female patients with cirrhosis, hormone replacement had no effect on all-cause mortality, fractures, liver-related mortality, liver transplantation, liver-related morbidity, serum bilirubin concentration nor lumbar spine bone mineral density. On the contrary, hormone replacement significantly increased the frequency of adverse events[60].

***Wilson disease***

Although this autosomic recessive disorder characterized by a wide spectrum of clinical manifestations should theoretically be present in females and males in equal proportion[61], a slight female predominance has been reported[62] partly reflecting the variable penetrance of genetic mutations that cause this disease. More significantly, however, neurological symptoms have been more frequently associated with female gender (*P* = 0.051) and with an acute, often fulminant course upon presentation when there is hepatic involvement (*P* = 0.046)[63]. In a French study analyzing medical records of 121 patients who underwent LT for Wilson Disease, male gender, pre-transplant renal insufficiency, non-elective procedure, and neurological indication for LT were significantly associated with poorer survival rate (*P* = 0.04) at univariate analysis. However, none of these factors remained statistically significant on multivariate analysis[64].

***Alcohol***

Alcohol has been demonstrated to exert a more deleterious effect in women and female animal models with respect to males[65], which can partly be explained by lower levels of gastric alcohol dehydrogenase in females, resulting in lower alcohol threshold for women[66]. Moreover, acute liver injury develops more rapidly and more extensively in women than in men even for a smaller quantity consumed[67]. Ethanol has been demonstrated to increase TNF-alpha mRNA expression and cause more severe acute liver injury in females[68]. Interestingly, estrogens have a major influence on Kupffer cell reactivity and proinflammatory cytokine production, and this could constitute a major determinant of women’s increased risk of alcohol-induced liver disease[69].

***Drug-induced liver injury and gender***

Different patterns of drug-induced liver damage between males and females have been recognized both in humans[70] as well as in animal models[71]. It has been reported that overall, women have a 1.5- to 1.7-fold greater risk of developing adverse drug reactions than men[72], and a prospective, multicenter study based on intensive pharmacovigilance confirmed a higher risk of acute adverse drug reactions in women vs men[73]. Excluding behavioural or dosing differences, there are three main hypotheses regarding the mechanisms behind these differences, including: (1) different pharmacokinetics between females and males; (2) gender-specific hormonal effects or interaction with signalling molecules that may affect drug safety; and (3) differences in aberrant immune response that targets the liver following drug exposure that can result in adverse drug reactions[70]. Gender-based differences that may have an impact on drug pharmacokinetics and subsequent toxicity include differences in gastrointestinal blood flow, gastric acid secretion, relative amount of circulating drug-binding proteins, relative proportions of muscular and adipose tissue, renal blood flow, gender-specific expression of cytochrome P450 (CYP450) isozymes, as well as physiologic and hormonal changes during the menstrual cycle, during pregnancy and after menopause[74].

A study based on World Health Organization-endorsed VigiBase™, the largest and most comprehensive database on global “Individual Case Safety Reports”, analyzed gender and age differences in reporting of drug-induced hepatic failure for a 10-year period (2000-2009). From a total of 6370 reports from 38 countries, and excluding missing gender data in 379 cases, females accounted for 54.03% of cases. The largest proportion of hepatic failure cases corresponded to patients younger than 55 years (42.57%), with a female predominance (56.81%), whereas gender was almost evenly distributed in the group above 55 years of age. Regarding drug types, there was a significant female preponderance in hepatic failure associated with analgesics, antiepileptics, anti-inflammatory and antirrheumatic agents, antidiabetics, and antibacterials for systemic use, whereas males were significantly overrepresented in hepatic failure cases associated with antivirals[75].

Female gender is more frequently associated with paracetamol overdose, which fortunately only in a fraction of patients leads to acute liver injury and acute liver failure; in a study from Iceland analyzing 1913 drug-related poisoning episodes, of which 352 involved paracetamol overdoses, the female/male ratio was 3.0, and the principal age group was 16-25 years. However, amongst those who required hospitalization, 16% were accidental overdoses and there were no gender differences[76].

***Hepatocellular carcinoma***

In spite of the striking preponderance of male sex amongst patients with HCC, probably estrogens play a very important role in liver carcinogenesis[77] and wild-type vs variant estrogen receptors in the liver accurately predict survival in patients with HCC[78]. If transplant centers maintain the adopted trend of allocating nearly 17-40% of organs to patients who have HCC[19,79], women, whom are listed for LT less frequently for this indication, will have a reduced access to LT with respect to men, since while men will have theoretically 100% of organs available, women will have to “compete” against men for the remaining organs allocated to non-HCC indications for LT.

Notwithstanding the fact that HCC affects men more frequently, and that previous database studies had found gender disparities favouring men in rates of LT in cohorts of HCC patients only, a recent retrospective US database analysis spanning 10 years and over 40,000 patients[80] demonstrated that women with HCC present less often with decompensated liver disease (OR = 0.79, *P* < 0.001), and are more likely to receive invasive HCC treatment, with significantly higher rates of resection across different ethnicities and diagnoses (OR = 1.34 and 1.44, *P* < 0.001). In this study, univariate analysis showed that although women have lower unadjusted rates of LT, disparity resolves after controlling for other clinical and demographic factors[80].

### ISSUES OF SIZE AND GENDER IN DONOR-RECIPIENT MATCHING

Liver donor size mismatch has been proposed as partially accountable for the disparity between LT rates between male and female patients[2]. A large study based on the OPTN demonstrated that, controlling for region and blood type, women were 25% less likely to undergo LT in a given month in comparison with men (*P* < 0.001). Including gender within the model increased the OR for this variable to 0.84. Of this 25%, 9% was found to be attributable to MELD score. Stemming from this study, an additional 3% increase in the OR for gender (0.87, *P* < 0.001) is imputable to estimated liver volume (mean estimated liver volume was significantly lower for female patients than for male patients on the LT waiting list, *P* < 0.001), therefore partly explaining gender disparity in LT rates[81]. Henceforth, even after accounting for MELD score and estimated liver size, approximately half of the 25% gender disparity remains unexplained.

In fact, other relevant factors related to survival on the waiting list for LT, such as the metabolic and nutritional status, are not accounted for by the MELD score. Notwithstanding the fact that in general women are characterized by less muscle mass than men, this difference is furthermore often not evaluated nor compensated for with adequate formulas[82]. The standardized triceps skinfold thickness (TST) and mid-arm muscular circumference determinations, which are more adequate for evaluation of nutritional status than body mass index in patients with ascites, were found to be lower in female patients[83]. Moreover, in a recent study analyzing pretransplant muscle mass on more than 300 LT recipients, of whom 68% could have been defined as cachectic, in female patients, muscle mass predicted intensive care unit stay, total length of stay, and days of intubation, but did not predict survival after LT (mean follow-up of 2.8 years)[84].

The impact of gender mismatch between donors and recipients on the outcome of LT is still a matter of debate, and may differ amongst deceased-donor LT (DDLT), living-donor LT (LDLT), and pediatric LDLT. Lehner *et al*[85] reported that gender mismatch does not play a role in the outcome of LT. On the contrary, some studies have reported on the negative impact of gender mismatch on graft failure, specifically regarding male recipients who receive grafts from female donors in DDLT[86–89]. Furthermore, a recently published prospective study analyzing outcomes of 1042 LT recipients demonstrated that graft survival in patients who received an organ matched for their gender was better than those receiving a gender mismatch (*P* = 0.047), and the worst combination was female-to-male LT (*P* < 0.001) [90] .

Regarding LDLT, a male recipient receiving a graft from a female donor was shown to be an independent risk factor for recipient mortality in adults[91], while in pediatric LDLT, an interesting finding has been that recipients of maternal grafts have reportedly lower rates of graft failure and refractory rejection in contrast with recipients of paternal grafts.[92] In the specific setting of HCV infection, no difference has been observed in terms of graft nor patient survival according to donor-recipient gender matching[93].

Being smaller, female patients have a limited access to the pool of available organs, and may have to wait longer for organs of an appropriate size, since livers from pediatric donors are preferentially allocated to children awaiting LT. Further increasing this disparity is the fact that a small organ may be adequate for a large individual, but the contrary is not always possible[2].

Interestingly, a Japanese study analyzing 114 LDLT using parental grafts performed for recipients with biliary atresia demonstrated that gender mismatch alone was an independent risk factor for acute cellular rejection (*P* = 0.012), and paternal grafts with gender mismatch were associated with a higher incidence of acute cellular rejection with respect to maternal grafts with gender match (*P* = 0.002)[94]. The authors infer that maternal antigens may have an important clinical impact on graft tolerance in LDLT, which is in line with what was first hypothesized by Starzl and collaborators[95] regarding induction of tolerance by microchimerism, and what has been demonstrated regarding non-inherited maternal antigens and maternal microchimerism in blood and various organs[96,97]. Exposure to maternal antigens, in fact, may have tolerogenic effects on offspring, resulting in acceptance or rejection of allografts expressing the maternal antigens[98], although a functional linkage between microchimerism and tolerance has been difficult to establish[99,100].

Another factor that might play a relevant role in gender-matching is the different hormonal array regarding estrogens (and their receptors). Female-to-female matched LT have been associated with a decreased risk of graft failure with respect to male-male matched transplants, but only for non-HCV female recipients[86]. In animal models, a greater degree of hepatic lactic acidosis during warm ischemia has been demonstrated to occur in females with respect to males[101], which may provide a potential metabolic explanation for the worse outcome in recipients of female donors. However, the matter entails complex aspects that have not yet been fully understood, and this is reflected by the disparity in reports on the role of estrogens in ischemia-reperfusion[102–105]. Apparently, females are more susceptible to hepatic reperfusion injury, but experimental data in the mouse model have shown that estrogens actually reduce ischemia/reperfusion damage[106]. The mechanisms for sex differences in the liver’s metabolic response to ischemia do seem, however, to be estrogen-mediated, even in the presence of male hormones[107].

However, again, not all of these differences may be attributable to hormone status solely, but may actually represent an immunological basis. Late-presenting nonanastomotic biliary strictures after LT have been reported to occur more frequently in female-male gender donor-recipient matches, as well as in patients transplanted for primary sclerosing cholangitis, and in patients in whom Roux-en-Y bile duct reconstructions were performed[108], and while ischemia and preservation factors seem to play a preponderant role in early-presenting non-anastomotic biliary strictures, immunological factors are the predominant factor in late-presenting non-anastomotic biliary structures. Interestingly, the fact that immunological processes are implied, does not rule out the fact that still poorly understood linkages between hormones, hormonal receptor, and immunological mechanisms exist.

**OUTCOMES AFTER LIVER TRANSPLANTATION IN FEMALE RECIPIENTS**

Overall outcomes after LT, especially in the long-term, are reportedly better in women[24] with respect to men. A 20-year follow-up study of 313 LT recipients revealed that, together with primary indication (*P* < 0.001), age (*P* < 0.001), impaired renal function at 6 months (*P* < 0.001) and retransplantation (*P* = 0.034), gender (*P* = 0.017) had a significant impact on patient survival[109]. The reported protective effect of female gender in the development of metabolic complications related to hyperglycemia[109] has been confirmed in other series as well; a study based on the OPTN/United Network Sharing (UNOS) database including 19,582 DDLT non-diabetic recipients (in whom the incidence of new-onset diabetes after transplantation (NODAT) has been established to be greater with respect to LDLT recipients), demonstrated that male sex was a predictor for NODAT, while this was not the case for LDLT recipients[110].

After LT, de novo NASH or non-alcoholic fatty liver disease (NAFLD) reportedly develop in 20% and 10% of cases, respectively[92], while approximately 50% of patients transplanted for NASH will experience recurrence[90], with 5% to 10% of patients progressing to cirrhosis[91]. Importantly, menopausal status, which is associated with weight gain and increased central fat mass[111], constitutes a risk factor for developing NASH and metabolic syndrome; in a long-term observational study spanning 12 years, metabolic syndrome was a significant risk factor for mortality in postmenopausal women compared to men and premenopausal women [93].

Regarding renal function, as mentioned above, in a recent study, female gender was found to be an independent and significant predictor of advanced stages of CKD at 1 year post-LT (OR, 2.96, *P* < 0.001) and at 5 years post-LT (OR, 2.52, *P* = 0.004)[45], and results from the MOST study had revealed that 1-year GFR is significantly affected both by HCV infection and recipient female gender (*P* < 0.01 for both)[112].

The impact of gender on outcomes after LT varies according to the indication for LT. Along with recurrent HCC (*P* < 0.001) and retransplantation (*P* = 0.01), female gender (*P* = 0.002) has been significantly associated with worse survival after LT for Hepatitis B, as shown in a multicentre US study pooling 738 LT recipients[113]. Concerning HCV, post-LT recurrence is nearly universal[114–116], and female gender has been described as a risk factor for severe HCV recurrence and graft lost after LT, and the risk increases with increasing donor age[86,117,118]. The important fibrosis suppression effect of estrogens demonstrated experimentally in animal models[119,120] is reflected in the clinically slower fibrosis progression observed in women with respect to men in chronic HCV[121,122]. However, most LT female recipients are post-menopausal, and the lower estrogenic levels associated with this state have been clinically associated with higher degrees of fibrosis[30,123]. Although in immune-competent HCV-infected women menopause is per se frequently associated with steatosis, which is an important cofactor for disease progression[118,124], another hypothesis is that women who require LT are the ones with genetic, virological and immunological factors that determine a more severe course of HCV-related disease, leading to LT, which in turn progresses more rapidly after LT[117]. Moreover, female gender has been shown to be an independent negative prognostic factor for the outcome of HCV antiviral therapy after LT[125]. Although male and female patients did not differ in HCV viral load, histology, or rate of diabetes at baseline, SVR was significantly lower in females than in males (29.5% *vs* 42.1%; *P* = 0.03). Partly explaining this unfavorable response rate, the authors found that compliance to therapy was also significantly lower in women with respect to men (43.4% *vs* 23.8%; *P* = 0.001), and that anemia was the main reason for lower adherence. On multivariate analysis, female gender (*P* < 0.04), early virological response (*P* < 0.0001), and adherence to therapy (*P* < 0.0001) were independent predictors for SVR[126].

**SPECIAL ISSUES REGARDING LIVER TRANSPLANTATION AND GENDER**

***Bone metabolism***

Immunosuppressive medication is a major contributor to osteoporosis in the post transplant period[127,128], and post-menopausal women are at higher risk for developing osteoporosis compared to women in the fertile age, as a consequence of decreased serum estrogen levels[129]. The predominant deleterious effects of steroids on bone metabolism include reduced bone formation by decreasing osteoblast replication and differentiation, and increased apoptosis[130,131]. Among calcineurin inhibitors, cyclosporine has increase bone turnover[132], whereas tacrolimus may cause less bone loss[133,134]. A prospective study evaluated 23 women who underwent LT, of whom 13% were peri-menopausal and 56.5% were post-menopausal, finding that in peri- and post-menopausal women, an inferior bone mass was observed in 81.2% of patients: of whom 50% diagnosed with having low bone mass and 31.2% with osteoporosis. Moreover, the postmenopausal stage was signiﬁcantly associated with a decreased bone mass (*P* < 0.0001)[135].

***2.Risk of de novo malignancy***

Aside from the risks concerning bone disease, immunosuppression increases the probability of de novo tumors[136–138]; in a multicentric Italian study showed that the risk for some types of tumors was particularly and significantly higher in women, specifically carcinomas of tongue, all tumors of the oral cavity, and head/neck cancers[139]. In contrast, a smaller study analyzing predictors of de novo malignancies in 534 LT recipients, did not find gender to play a role[140].

***Sexual life, fertility and pregnancy***

Reproductive function is often severely compromised in women with advanced liver disease, and is frequently characterized by menstrual irregularity, amenorrhea, and infertility in nearly half of patients[141,142]. Etiologies of chronic liver disease which more frequently affect female patients, such as autoimmune hepatitis, may worsen during the course of pregnancy, as most diseases of autoimmune origin, with flares of disease activity reported in 7%-21% and 11-86% of women during the gestational period and during the post-partum period, respectively[141,143–146]. Although maternal outcomes are generally favorable, pregnancy has been reportedly the trigger for hepatic decompensation (leading to LT in some cases) and maternal death (including liver-related death), with fetal outcomes which are lower than those of the general population, but comparable to those of other autoimmune diseases[141,143–147]. In the study by Westbrook and collaborators[147], of 81 pregnancies in 53 autoimmune hepatitis patients, 41% took place in the context of cirrhosis, and live birth rate was significantly lower within this category. Furthermore, a serious maternal adverse event (death or need for LT) during or within 12-mo of delivery, or hepatic decompensation during or within 3-mo of delivery, occurred with 9 pregnancies (11%) and was more common in women with cirrhosis (*P* = 0.028), and patients who experienced a flare in association with pregnancy were more likely to develop hepatic decompensation (*P* = 0.01)[147]. As flares are more frequent in patients who are not on therapy or who have had a disease flare in the year prior to conception and, pre-conception counselling and adequate gestational management are paramount.

In general, an elevated percentage of women are sexually active after LT[148,149]. Approximately 70% of transplant recipients in a study from Brazil were reportedly sexually active after a median of 36 months after successful LT[150], whereas decreased libido and difficulty to reach orgasm with intercourse has been described in 26% of female LT recipients[151]. Successful LT restores menstrual function in 97% of female patients, as well as childbearing potential[152–154]. In general, LT leads to partial or complete normalization of both levels of sex hormones and sexual function within several months of LT[155], with nearly 48% of women in their fertile age experiencing regular menses, 26% irregular bleeding, and 26% amenorrhea[153], while more than 60% of peri-menopausal women reportedly experience a higher frequency of menstrual pattern disorders[156]. In the United States only, approximately 14000 women of childbearing age are currently LT recipients, and another 500 women will undergo LT annually[24]. The optimal timing of conception is still a matter of debate, but waiting at least 1 year after LT is generally recommended[157]. Regarding immunosuppression, calcineurin inhibitors and steroids can be used safely, while azathioprine and mycophenolate mofetil have been associated with increased toxic effects[158]. Pregnancy outcomes after LT are acceptable in terms of the health of the mother and of the newborn[159], and reportedly better in comparison to those obtained after kidney transplantation, with significantly lower rates of hypertension, preeclampsia, preterm deliveries, and birth of neonates small for their gestational age[160].

In a study from Vienna assessing 39 deliveries and 40 live births[161], the mean time from organ transplantation to delivery was 67.6 ± 47.2 mo. A meta-analysis on 450 pregnancies in 306 LT recipients showed that although the rates of pre-eclampsia (21.9%), caesarean section delivery (44.6%), and preterm delivery (39.4%) were higher than the rates for the US general population (3.8%, 31.9%, and 12.5%, respectively), the post-LT live birth rate (76.9%) was higher than the live birth rate for the US general population (66.7%), and the post-LT miscarriage rate (15.6%) was lower than the miscarriage rate for the general population (17.1%)[162].

***Quality of life after liver transplantation***

In a German cross-sectional, single-center study evaluating the quality of life in 281 LT recipients[163], similar results were observed between male and female subjects, whereas in another study analyzing gender differences after HCV-related LT, however, it emerged that male subjects score significantly higher on physical role functioning and physical activity compared with females, whereas women had reportedly better quality of life compared to males with regard to the emotional state and mental health 1-year after LT[164].

**CONCLUSION**

Important gender differences exist regarding etiologies of liver disease, severity of the course of these diseases, and on outcomes after LT. Unfortunately, access to LT is still governed by an imperfect allocation system, currently based on MELD score, which includes systematic biases against women, but is also hampered by factors that are not adequately taken into account by MELD score, doubly penalizing the female gender. A later access to LT wait-listing and subsequently to LT due to renal dysfunction underestimation, is a determinant factor that has an impact on post-transplant renal function as well, whereas being generally smaller than men, organ allocation decisions generally favor children as recipients of small organs, and men as recipients of large organs, conditioning a longer waiting time for an organ.

Throughout women’s life, profound hormonal changes also determine the natural course of diseases; while estrogens may protect against inflammation and fibrosis during the fertile age, the post-menopausal status takes a high toll on disease progression both before and after LT, and may be further complicated by obesity, NASH, NAFLD, and other components of the metabolic syndrome. The above are summarized in Table 1 (Key points). It is therefore ever clearer that special attention should be paid in the integral management of women during the different life periods, and with respect to special situations regarding natural evolution and risk factors for liver disease, as well as to those affecting post-transplant outcome.

**ACKNOWLEDGEMENTS**

The authors would like to acknowledge all members of Women in Hepatology Group: Erica Villa, Modena, Italy (Chair);Anna Alisi, Rome, Italy; Clara Balsano, Rome, Italy; Veronica Bernabucci, Modena, Italy; Annalisa Berselli, Modena, Italy; Annalisa Berzigotti, Barcelona, Spain/Bologna, Italy; Elena Bertolini, Modena Italy; Maurizia Brunetto, Pisa Italy; Elisabetta Bugianesi, Turin, Italy; Patrizia Burra, Padua, Italy; Vincenza Calvaruso, Palermo Italy; Elisabetta Cariani, Modena Italy; Alessia Ciancio, Turin, Italy; Barbara Coco, Pisa, Italy; Isabelle Colle, Bruxelles, Belgium; Eleonora De Martin, Padua, Italy; Mariagrazia Del Buono, Modena, Italy; Giovanna Fattovich, Verona, Italy; Annarosa Floreani, Padua, Italy; Guadalupe Garcia-Tsao, New Haven, United States; Chantal Housset, Paris, France; Aimilia Karampatou, Modena, Italy; Barbara Lei, Modena, Italy; Anna Licata, Palermo, Italy; Alessandra Mangia, San Giovanni Rotondo, Italy; Maria Luz Martinez-Chantar, Bilbao, Spain; Filomena Morisco, Naples, Italy; Paola Nasta, Brescia, Italy; Tomris Ozben, Antalya, Turkey; Teresa Pollicino, Messina, Italy; Maria Laura Ponti, Cagliari, Italy; Patrizia Pontisso, Padua, Italy; Helen Reeves, Newcasatle, United Kingdom;Maria Rendina, Bari, Italy; Kryssia I Rodríguez-Castro, Padua, Italy; Caterina Sagnelli, Salerno, Italy; Teresa Santantonio, Foggia, Italy; Giada Sebastiani, Venice, Italy; Antonella Smedile, Turin, Italy; Gloria Taliani, Rome, Italy; Carmen Vandelli, Modena, Italy; Ranka Vukotic, Modena, Italy; Anna Linda Zignego, Florence, Italy.

**REFERENCES**

1 **Bryce CL**, Angus DC, Arnold RM, Chang CC, Farrell MH, Manzarbeitia C, Marino IR, Roberts MS. Sociodemographic differences in early access to liver transplantation services. *Am J Transplant* 2009; **9**: 2092-2101 [PMID: 19645706 DOI: 10.1111/j.1600-6143.2009.02737.x]

2 **Axelrod DA**, Pomfret EA. Race and sex disparities in liver transplantation: progress toward achieving equal access? *JAMA* 2008; **300**: 2425-2426 [PMID: 19033595 DOI: 10.1001/jama.2008.732]

3 **Klassen AC**, Klassen DK, Brookmeyer R, Frank RG, Marconi K. Factors influencing waiting time and successful receipt of cadaveric liver transplant in the United States, 1990 to 1992. *Med Care* 1998; **36**: 281-294 [PMID: 9520954]

4 **Moylan CA**, Brady CW, Johnson JL, Smith AD, Tuttle-Newhall JE, Muir AJ. Disparities in liver transplantation before and after introduction of the MELD score. *JAMA* 2008; **300**: 2371-2378 [PMID: 19033587 DOI: 10.1001/jama.2008.720]

5 **Mathur AK**, Schaubel DE, Gong Q, Guidinger MK, Merion RM. Sex-based disparities in liver transplant rates in the United States. *Am J Transplant* 2011; **11**: 1435-1443 [PMID: 21718440 DOI: 10.1111/j.1600-6143.2011.03498.x]

6 **Fink MA**, Berry SR, Gow PJ, Angus PW, Wang BZ, Muralidharan V, Christophi C, Jones RM. Risk factors for liver transplantation waiting list mortality. *J Gastroenterol Hepatol* 2007; **22**: 119-124 [PMID: 17201891 DOI: 10.1111/j.1440-1746.2006.04422.x]

7 **Myers RP**, Shaheen AA, Aspinall AI, Quinn RR, Burak KW. Gender, renal function, and outcomes on the liver transplant waiting list: assessment of revised MELD including estimated glomerular filtration rate. *J Hepatol* 2011; **54**: 462-470 [PMID: 21109324 DOI: 10.1016/j.jhep.2010.07.015]

8 **Mariante-Neto G**, Marroni CP, Fleck Junior AM, Marroni CA, Zanotelli ML, Cantisani G, Brandão AB. Impact of creatinine values on MELD scores in male and female candidates for liver transplantation. *Ann Hepatol* 2013; **12**: 434-439 [PMID: 23619260]

9 **Wiesner RH**. Patient selection in an era of donor liver shortage: current US policy. *Nat Clin Pract Gastroenterol Hepatol* 2005; **2**: 24-30 [PMID: 16265097 DOI: 10.1038/ncpgasthep0070]

10 **Leuschner U**. Primary biliary cirrhosis--presentation and diagnosis. *Clin Liver Dis* 2003; **7**: 741-758 [PMID: 14594129]

11 **Mela M**, Mancuso A, Burroughs AK. Review article: pruritus in cholestatic and other liver diseases. *Aliment Pharmacol Ther* 2003; **17**: 857-870 [PMID: 12656688]

12 **Levy C**, Lindor KD. Management of Primary Biliary Cirrhosis. *Curr Treat Options Gastroenterol* 2003; **6**: 493-498 [PMID: 14585238]

13 **Freeman RB**, Wiesner RH, Harper A, McDiarmid SV, Lake J, Edwards E, Merion R, Wolfe R, Turcotte J, Teperman L. The new liver allocation system: moving toward evidence-based transplantation policy. *Liver Transpl* 2002; **8**: 851-858 [PMID: 12200791 DOI: 10.1053/jlts.2002.35927]

14 **Mazzaferro V**, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, Montalto F, Ammatuna M, Morabito A, Gennari L. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. *N Engl J Med* 1996; **334**: 693-699 [PMID: 8594428 DOI: 10.1056/NEJM199603143341104]

15 **Figueras J**, Jaurrieta E, Valls C, Ramos E, Serrano T, Rafecas A, Fabregat J, Torras J. Resection or transplantation for hepatocellular carcinoma in cirrhotic patients: outcomes based on indicated treatment strategy. *J Am Coll Surg* 2000; **190**: 580-587 [PMID: 10801025]

16 **Pomfret EA**, Washburn K, Wald C, Nalesnik MA, Douglas D, Russo M, Roberts J, Reich DJ, Schwartz ME, Mieles L, Lee FT, Florman S, Yao F, Harper A, Edwards E, Freeman R, Lake J. Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States. *Liver Transpl* 2010; **16**: 262-278 [PMID: 20209641 DOI: 10.1002/lt.21999]

17 **Llovet JM**, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. *Hepatology* 1999; **30**: 1434-1440 [PMID: 10573522 DOI: 10.1002/hep.510300629]

18 **Liver allocation policy.** http: //optn.transplant.hrsa.gov/PoliciesandBylaws2/policies/pdfs/ policy\_8.pdf. 2012. Last accessed March 2014

19 **Adam R**, Karam V, Delvart V, O'Grady J, Mirza D, Klempnauer J, Castaing D, Neuhaus P, Jamieson N, Salizzoni M, Pollard S, Lerut J, Paul A, Garcia-Valdecasas JC, Rodríguez FS, Burroughs A. Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR). *J Hepatol* 2012; **57**: 675-688 [PMID: 22609307 DOI: 10.1016/j.jhep.2012.04.015]

20 **Sharma P**, Balan V, Hernandez JL, Harper AM, Edwards EB, Rodriguez-Luna H, Byrne T, Vargas HE, Mulligan D, Rakela J, Wiesner RH. Liver transplantation for hepatocellular carcinoma: the MELD impact. *Liver Transpl* 2004; **10**: 36-41 [PMID: 14755775 DOI: 10.1002/lt.20012]

21 **Washburn K**, Edwards E, Harper A, Freeman R. Hepatocellular carcinoma patients are advantaged in the current liver transplant allocation system. *Am J Transplant* 2010; **10**: 1643-1648 [PMID: 20486906 DOI: 10.1111/j.1600-6143.2010.03127.x]

22 **Volk ML**. Unfair priority for HCC: A problem whose ideal solution remains unsolved. *Am J Transplant* 2010; **10**: 1507-1508 [PMID: 20642675 DOI: 10.1111/j.1600-6143.2010.03154.x]

23 **Mindikoglu AL**, Regev A, Seliger SL, Magder LS. Gender disparity in liver transplant waiting-list mortality: the importance of kidney function. *Liver Transpl* 2010; **16**: 1147-1157 [PMID: 20879013 DOI: 10.1002/lt.22121]

24 **Liver transplantation between 1988 and 2013 in the United States.** http: //optn.transplan.hrsa.gov/latestData/rptData.asp. Last accessed February 2014

25 **Barrett S**, Goh J, Coughlan B, Ryan E, Stewart S, Cockram A, O'Keane JC, Crowe J. The natural course of hepatitis C virus infection after 22 years in a unique homogenous cohort: spontaneous viral clearance and chronic HCV infection. *Gut* 2001; **49**: 423-430 [PMID: 11511566]

26 **Pagliaro L**, Peri V, Linea C, Cammà C, Giunta M, Magrin S. Natural history of chronic hepatitis C. *Ital J Gastroenterol Hepatol* 1999; **31**: 28-44 [PMID: 10091101]

27 **Burra P**, De Martin E, Gitto S, Villa E. Influence of age and gender before and after liver transplantation. *Liver Transpl* 2013; **19**: 122-134 [PMID: 23172830 DOI: 10.1002/lt.23574]

28 **De Martin E**, Rodriguez-Castro K, Gambato M, Villa E, Burra P. (2014) Women after Liver Transplantation. *Organs, Tissues and Cells* 2014; In press.

29 **Leone N**, Rizzetto M. Natural history of hepatitis C virus infection: from chronic hepatitis to cirrhosis, to hepatocellular carcinoma. *Minerva Gastroenterol Dietol* 2005; **51**: 31-46 [PMID: 15756144]

30 **Di Martino V**, Lebray P, Myers RP, Pannier E, Paradis V, Charlotte F, Moussalli J, Thabut D, Buffet C, Poynard T. Progression of liver fibrosis in women infected with hepatitis C: long-term benefit of estrogen exposure. *Hepatology* 2004; **40**: 1426-1433 [PMID: 15565616 DOI: 10.1002/hep.20463]

31 **Villa E**, Karampatou A, Cammà C, Di Leo A, Luongo M, Ferrari A, Petta S, Losi L, Taliani G, Trande P, Lei B, Graziosi A, Bernabucci V, Critelli R, Pazienza P, Rendina M, Antonelli A, Francavilla A. Early menopause is associated with lack of response to antiviral therapy in women with chronic hepatitis C. *Gastroenterology* 2011; **140**: 818-829 [PMID: 21167831 DOI: 10.1053/j.gastro.2010.12.027]

32 **Villa E**, Vukotic R, Cammà C, Petta S, Di Leo A, Gitto S, Turola E, Karampatou A, Losi L, Bernabucci V, Cenci A, Tagliavini S, Baraldi E, De Maria N, Gelmini R, Bertolini E, Rendina M, Francavilla A. Reproductive status is associated with the severity of fibrosis in women with hepatitis C. *PLoS One* 2012; **7**: e44624 [PMID: 22970270 DOI: 10.1371/journal.pone.0044624]

33 **Neuman MG**, Benhamou JP, Malkiewicz IM, Akremi R, Shear NH, Asselah T, Ibrahim A, Boyer N, Martinot-Peignoux M, Jacobson-Brown P, Katz GG, Le Breton V, Le Guludec G, Suneja A, Marcellin P. Cytokines as predictors for sustained response and as markers for immunomodulation in patients with chronic hepatitis C. *Clin Biochem* 2001; **34**: 173-182 [PMID: 11408014]

34 **Villa E**, Cammà C, Di Leo A, Karampatou A, Enea M, Gitto S, Bernabucci V, Losi L, De Maria N, Lei B, Ferrari A, Vukotic R, Vignoli P, Rendina M, Francavilla A. Peginterferon-Α\_2B plus ribavirin is more effective than peginterferon-Α\_2A plus ribavirin in menopausal women with chronic hepatitis C. *J Viral Hepat* 2012; **19**: 640-649 [PMID: 22863268 DOI: 10.1111/j.1365-2893.2012.01593.x]

35 **Rifai K**, Hadem J, Wiegand J, Potthoff A, Pischke S, Klempnauer J, Strassburg C, Wedemeyer H, Manns MP, Tillmann HL. Gender differences in patient receiving liver transplantation for viral hepatitis. *Z Gastroenterol* 2012; **50**: 760-765 [PMID: 22895904 DOI: 10.1055/s-0031-1281631]

36 **Khuroo MS**, Teli MR, Skidmore S, Sofi MA, Khuroo MI. Incidence and severity of viral hepatitis in pregnancy. *Am J Med* 1981; **70**: 252-255 [PMID: 6781338]

37 **Ramalingaswami V**, Purcell RH. Waterborne non-A, non-B hepatitis. *Lancet* 1988; **1**: 571-573 [PMID: 2894501]

38 **Tsega E**, Krawczynski K, Hansson BG, Nordenfelt E. Hepatitis E virus infection in pregnancy in Ethiopia. *Ethiop Med J* 1993; **31**: 173-181 [PMID: 8404882]

39 **Mateos Lindemann ML**, Morales JG, Fernández-Barredo S, Domínguez MR, García de la Hoz F, Halfon P, Pérez Gracia MT. Fulminant hepatitis E in a woman taking oral contraceptive medication. *Am J Trop Med Hyg* 2010; **82**: 12-15 [PMID: 20064988 DOI: 10.4269/ajtmh.2010.09-0436]

40 **United Network for Organ Sharing**. http: //optn.transplant.hrsa.gov/latestData/rptData.asp.2014. Last accessed February 2014

41 **European Liver Transplant Registry.** http: //www.eltr.org/spip.php?article161. Last accessed February 2014

42 **Charlton M**. Nonalcoholic fatty liver disease: a review of current understanding and future impact. *Clin Gastroenterol Hepatol* 2004; **2**: 1048-1058 [PMID: 15625647]

43 **Loomba R**, Sanyal AJ. The global NAFLD epidemic. *Nat Rev Gastroenterol Hepatol* 2013; **10**: 686-690 [PMID: 24042449 DOI: 10.1038/nrgastro.2013.171]

44 **Park CW**, Tsai NT, Wong LL. Implications of worse renal dysfunction and medical comorbidities in patients with NASH undergoing liver transplant evaluation: impact on MELD and more. *Clin Transplant* 2011; **25**: E606-E611 [PMID: 21958082 DOI: 10.1111/j.1399-0012.2011.01497.x]

45 **Fussner LA,** Charlton MR, Heimbach JK, Fan C, Dierkhising R, Coss E, Watt KD. The impact of gender and NASH on chronic kidney disease before and after liver transplantation. *Liver Int* 2013 [PMID: 24262002]

46 **Amadori A**, Zamarchi R, De Silvestro G, Forza G, Cavatton G, Danieli GA, Clementi M, Chieco-Bianchi L. Genetic control of the CD4/CD8 T-cell ratio in humans. *Nat Med* 1995; **1**: 1279-1283 [PMID: 7489409]

47 **Gilmore W**, Weiner LP, Correale J. Effect of estradiol on cytokine secretion by proteolipid protein-specific T cell clones isolated from multiple sclerosis patients and normal control subjects. *J Immunol* 1997; **158**: 446-451 [PMID: 8977221]

48 **Araneo BA**, Dowell T, Diegel M, Daynes RA. Dihydrotestosterone exerts a depressive influence on the production of interleukin-4 (IL-4), IL-5, and gamma-interferon, but not IL-2 by activated murine T cells. *Blood* 1991; **78**: 688-699 [PMID: 1830499]

49 **Manns MP**, Czaja AJ, Gorham JD, Krawitt EL, Mieli-Vergani G, Vergani D, Vierling JM. Diagnosis and management of autoimmune hepatitis. *Hepatology* 2010; **51**: 2193-2213 [PMID: 20513004 DOI: 10.1002/hep.23584]

50 **Miyake Y**, Iwasaki Y, Sakaguchi K, Shiratori Y. Clinical features of Japanese male patients with type 1 autoimmune hepatitis. *Aliment Pharmacol Ther* 2006; **24**: 519-523 [PMID: 16886918 DOI: 10.1111/j.1365-2036.2006.03013.x]

51 **Al-Chalabi T**, Underhill JA, Portmann BC, McFarlane IG, Heneghan MA. Impact of gender on the long-term outcome and survival of patients with autoimmune hepatitis. *J Hepatol* 2008; **48**: 140-147 [PMID: 18023911 DOI: 10.1016/j.jhep.2007.08.013]

52 **Nalbandian G**, Van de Water J, Gish R, Manns M, Coppel RL, Rudich SM, Prindiville T, Gershwin ME. Is there a serological difference between men and women with primary biliary cirrhosis? *Am J Gastroenterol* 1999; **94**: 2482-2486 [PMID: 10484012 DOI: 10.1111/j.1572-0241.1999.01380.x]

53 **Kim WR**, Lindor KD, Locke GR, Therneau TM, Homburger HA, Batts KP, Yawn BP, Petz JL, Melton LJ, Dickson ER. Epidemiology and natural history of primary biliary cirrhosis in a US community. *Gastroenterology* 2000; **119**: 1631-1636 [PMID: 11113084]

54 **Rubel LR**, Rabin L, Seeff LB, Licht H, Cuccherini BA. Does primary biliary cirrhosis in men differ from primary biliary cirrhosis in women? *Hepatology* 1984; **4**: 671-677 [PMID: 6745856]

55 **Newton JL**, Davidson A, Kerr S, Bhala N, Pairman J, Burt J, Jones DE. Autonomic dysfunction in primary biliary cirrhosis correlates with fatigue severity. *Eur J Gastroenterol Hepatol* 2007; **19**: 125-132 [PMID: 17272997 DOI: 10.1097/01.meg.0000252629.96043.67]

56 **Newton JL**, Hudson M, Tachtatzis P, Sutcliffe K, Pairman J, Burt JA, Jones DE. Population prevalence and symptom associations of autonomic dysfunction in primary biliary cirrhosis. *Hepatology* 2007; **45**: 1496-1505 [PMID: 17538969 DOI: 10.1002/hep.21609]

57 **Levy C**, Naik J, Giordano C, Mandalia A, O'Brien C, Bhamidimarri KR, Schiff ER, Martin P. Hispanics With Primary Biliary Cirrhosis Are More Likely to Have Features of Autoimmune Hepatitis and Reduced Response to Ursodeoxycholic Acid Than Non-Hispanics. *Clin Gastroenterol Hepatol* 2013: S1542-3565(13)01936-8 [PMID: 24361417 DOI: 10.1016/j.cgh.2013.12.010]

58 **Lucey MR**, Neuberger JM, Williams R. Primary biliary cirrhosis in men. *Gut* 1986; **27**: 1373-1376 [PMID: 3792920]

59 **Floreani A**, Mega A, Camozzi V, Baldo V, Plebani M, Burra P, Luisetto G. Is osteoporosis a peculiar association with primary biliary cirrhosis? *World J Gastroenterol* 2005; **11**: 5347-5350 [PMID: 16149144]

60 **Rudic JS**, Poropat G, Krstic MN, Bjelakovic G, Gluud C. Hormone replacement for osteoporosis in women with primary biliary cirrhosis. *Cochrane Database Syst Rev* 2011: CD009146 [PMID: 22161447 DOI: 10.1002/14651858.CD009146.pub2]

61 **Scheinberg IH**. Wilson's disease. *J Rheumatol Suppl* ; **7**: 90-93 [PMID: 6939890]

62 **Rodrigo Agudo JL**, Valdés Mas M, Vargas Acosta AM, Ortiz Sánchez ML, Gil del Castillo ML, Carballo Alvarez LF, Pons Miñano JA. [Clinical presentation, diagnosis, and long-term outcome of 29 patients with Wilson's disease]. *Rev Esp Enferm Dig* 2008; **100**: 456-461 [PMID: 18942896]

63 **Bruha R**, Marecek Z, Pospisilova L, Nevsimalova S, Vitek L, Martasek P, Nevoral J, Petrtyl J, Urbanek P, Jiraskova A, Ferenci P. Long-term follow-up of Wilson disease: natural history, treatment, mutations analysis and phenotypic correlation. *Liver Int* 2011; **31**: 83-91 [PMID: 20958917 DOI: 10.1111/j.1478-3231.2010.02354.x]

64 **Guillaud O**, Dumortier J, Sobesky R, Debray D, Wolf P, Vanlemmens C, Durand F, Calmus Y, Duvoux C, Dharancy S, Kamar N, Boudjema K, Bernard PH, Pageaux GP, Salamé E, Gugenheim J, Lachaux A, Habes D, Radenne S, Hardwigsen J, Chazouillères O, Trocello JM, Woimant F, Ichai P, Branchereau S, Soubrane O, Castaing D, Jacquemin E, Samuel D, Duclos-Vallée JC. Long term results of liver transplantation for Wilson's disease: experience in France. *J Hepatol* 2014; **60**: 579-589 [PMID: 24211743 DOI: 10.1016/j.jhep.2013.10.025]

65 **Meier Y**, Cavallaro M, Roos M, Pauli-Magnus C, Folkers G, Meier PJ, Fattinger K. Incidence of drug-induced liver injury in medical inpatients. *Eur J Clin Pharmacol* 2005; **61**: 135-143 [PMID: 15726344 DOI: 10.1007/s00228-004-0888-z]

66 **Soldin OP**, Mattison DR. Sex differences in pharmacokinetics and pharmacodynamics. *Clin Pharmacokinet* 2009; **48**: 143-157 [PMID: 19385708 DOI: 10.2165/00003088-200948030-00001]

67 **Thurman RG**. Sex-related liver injury due to alcohol involves activation of Kupffer cells by endotoxin. *Can J Gastroenterol* 2000; **14 Suppl D**: 129D-135D [PMID: 11110625]

68 **Kono H**, Wheeler MD, Rusyn I, Lin M, Seabra V, Rivera CA, Bradford BU, Forman DT, Thurman RG. Gender differences in early alcohol-induced liver injury: role of CD14, NF-kappaB, and TNF-alpha. *Am J Physiol Gastrointest Liver Physiol* 2000; **278**: G652-G661 [PMID: 10762620]

69 **Müller C**. Liver, alcohol and gender. *Wien Med Wochenschr* 2006; **156**: 523-526 [PMID: 17103288 DOI: 10.1007/s10354-006-0348-8]

70 **Amacher DE.** Female gender as a susceptibility factor for drug-induced liver injury. *Hum Exp Toxicol* 2013 [PMID: 24299907 DOI: 10.1177/0960327113512860]

71 **Sheng Y**, Liang Q, Deng Z, Ji L, Wang Z. Acetaminophen induced gender-dependent liver injury and the involvement of GCL and GPx. *Drug Discov Ther* 2013; **7**: 78-83 [PMID: 23715506]

72 **Rademaker M**. Do women have more adverse drug reactions? *Am J Clin Dermatol* 2001; **2**: 349-351 [PMID: 11770389]

73 **Zopf Y**, Rabe C, Neubert A, Gassmann KG, Rascher W, Hahn EG, Brune K, Dormann H. Women encounter ADRs more often than do men. *Eur J Clin Pharmacol* 2008; **64**: 999-1004 [PMID: 18604529 DOI: 10.1007/s00228-008-0494-6]

74 **Fletcher CV**, Acosta EP, Strykowski JM. Gender differences in human pharmacokinetics and pharmacodynamics. *J Adolesc Health* 1994; **15**: 619-629 [PMID: 7696281]

75 **Petronijevic M**, Ilic K. Associations of gender and age with the reporting of drug-induced hepatic failure: data from the VigiBase™. *J Clin Pharmacol* 2013; **53**: 435-443 [PMID: 23440959 DOI: 10.1002/jcph.3]

76 **Kjartansdottir I**, Bergmann OM, Arnadottir RS, Björnsson ES. Paracetamol intoxications: a retrospective population-based study in Iceland. *Scand J Gastroenterol* 2012; **47**: 1344-1352 [PMID: 22827594 DOI: 10.3109/00365521.2012.703236]

77 **Villa E**. Role of estrogen in liver cancer. *Womens Health (Lond Engl)* 2008; **4**: 41-50 [PMID: 19072450 DOI: 10.2217/17455057.4.1.41]

78 **Villa E**, Moles A, Ferretti I, Buttafoco P, Grottola A, Del Buono M, De Santis M, Manenti F. Natural history of inoperable hepatocellular carcinoma: estrogen receptors' status in the tumor is the strongest prognostic factor for survival. *Hepatology* 2000; **32**: 233-238 [PMID: 10915729 DOI: 10.1053/jhep.2000.9603]

79 **Liver transplantation for hepatocellular carcinoma**. http: //optn.transplant.hrsa.gov/latestData/ rptData.asp. Last accessed March 2014

80 **Cauble S**, Abbas A, Balart L, Bazzano L, Medvedev S, Shores N. United States women receive more curative treatment for hepatocellular carcinoma than men. *Dig Dis Sci* 2013; **58**: 2817-2825 [PMID: 23812858 DOI: 10.1007/s10620-013-2731-9]

81 **Mindikoglu AL**, Emre SH, Magder LS. Impact of estimated liver volume and liver weight on gender disparity in liver transplantation. *Liver Transpl* 2013; **19**: 89-95 [PMID: 23008117 DOI: 10.1002/lt.23553]

82 **Yoshizumi T**, Shirabe K, Nakagawara H, Ikegami T, Harimoto N, Toshima T, Yamashita Y, Ikeda T, Soejima Y, Maehara Y. Skeletal muscle area correlates with body surface area in healthy adults. *Hepatol Res* 2014; **44**: 313-318 [PMID: 23607375 DOI: 10.1111/hepr.12119]

83 **Campillo B**, Paillaud E, Uzan I, Merlier I, Abdellaoui M, Perennec J, Louarn F, Bories PN. Value of body mass index in the detection of severe malnutrition: influence of the pathology and changes in anthropometric parameters. *Clin Nutr* 2004; **23**: 551-559 [PMID: 15297091 DOI: 10.1016/j.clnu.2003.10.003]

84 **DiMartini A**, Cruz RJ, Dew MA, Myaskovsky L, Goodpaster B, Fox K, Kim KH, Fontes P. Muscle mass predicts outcomes following liver transplantation. *Liver Transpl* 2013; **19**: 1172-1180 [PMID: 23960026 DOI: 10.1002/lt.23724]

85 **Lehner F**, Becker T, Klempnauer J, Borlak J. Gender-incompatible liver transplantation is not a risk factor for patient survival. *Liver Int* 2009; **29**: 196-202 [PMID: 18673439 DOI: 10.1111/j.1478-3231.2008.01827.x]

86 **Lai JC**, Feng S, Roberts JP, Terrault NA. Gender differences in liver donor quality are predictive of graft loss. *Am J Transplant* 2011; **11**: 296-302 [PMID: 21219572 DOI: 10.1111/j.1600-6143.2010.03385.x]

87 **Rustgi VK**, Marino G, Halpern MT, Johnson LB, Umana WO, Tolleris C. Role of gender and race mismatch and graft failure in patients undergoing liver transplantation. *Liver Transpl* 2002; **8**: 514-518 [PMID: 12037781 DOI: 10.1053/jlts.2002.33457]

88 **Francavilla R**, Hadzic N, Heaton ND, Rela M, Baker AJ, Dhawan A, Mieli-Vergani G. Gender matching and outcome after pediatric liver transplantation. *Transplantation* 1998; **66**: 602-605 [PMID: 9753339]

89 **Brooks BK**, Levy MF, Jennings LW, Abbasoglu O, Vodapally M, Goldstein RM, Husberg BS, Gonwa TA, Klintmalm GB. Influence of donor and recipient gender on the outcome of liver transplantation. *Transplantation* 1996; **62**: 1784-1787 [PMID: 8990363]

90 **Croome KP**, Segal D, Hernandez-Alejandro R, Adams PC, Thomson A, Chandok N. Female donor to male recipient gender discordance results in inferior graft survival: a prospective study of 1,042 liver transplants. *J Hepatobiliary Pancreat Sci* 2014; **21**: 269-274 [PMID: 24123790 DOI: 10.1002/jhbp.40]

91 **Yoshizumi T**, Shirabe K, Taketomi A, Uchiyama H, Harada N, Ijichi H, Yoshimatsu M, Ikegami T, Soejima Y, Maehara Y. Risk factors that increase mortality after living donor liver transplantation. *Transplantation* 2012; **93**: 93-98 [PMID: 22203391 DOI: 10.1097/TP.0b013e318238dacd]

92 **Nijagal A**, Fleck S, Hills NK, Feng S, Tang Q, Kang SM, Rosenthal P, MacKenzie TC. Decreased risk of graft failure with maternal liver transplantation in patients with biliary atresia. *Am J Transplant* 2012; **12**: 409-419 [PMID: 22221561 DOI: 10.1111/j.1600-6143.2011.03895.x]

93 **Grąt M**, Kornasiewicz O, Lewandowski Z, Ligocka J, Grąt K, Wronka KM, Zieniewicz K, Krawczyk M. Post-transplant outcomes of patients with and without hepatitis C virus infection according to donor age and gender matching. *Ann Transplant* 2013; **18**: 705-715 [PMID: 24361968 DOI: 10.12659/AOT.889537]

94 **Sanada Y**, Kawano Y, Miki A, Aida J, Nakamura K, Shimomura N, Ishikawa N, Arai T, Hirata Y, Yamada N, Okada N, Wakiya T, Ihara Y, Urahashi T, Yasuda Y, Takubo K, Mizuta K. Maternal grafts protect daughter recipients from acute cellular rejection after pediatric living donor liver transplantation for biliary atresia. *Transpl Int* 2014; **27**: 383-390 [PMID: 24472036 DOI: 10.1111/tri.12273]

95 **Starzl TE**, Demetris AJ, Trucco M, Ramos H, Zeevi A, Rudert WA, Kocova M, Ricordi C, Ildstad S, Murase N. Systemic chimerism in human female recipients of male livers. *Lancet* 1992; **340**: 876-877 [PMID: 1357298]

96 **Loubière LS**, Lambert NC, Flinn LJ, Erickson TD, Yan Z, Guthrie KA, Vickers KT, Nelson JL. Maternal microchimerism in healthy adults in lymphocytes, monocyte/macrophages and NK cells. *Lab Invest* 2006; **86**: 1185-1192 [PMID: 16969370 DOI: 10.1038/labinvest.3700471]

97 **Maloney S**, Smith A, Furst DE, Myerson D, Rupert K, Evans PC, Nelson JL. Microchimerism of maternal origin persists into adult life. *J Clin Invest* 1999; **104**: 41-47 [PMID: 10393697 DOI: 10.1172/JCI6611]

98 **Dutta P**, Burlingham WJ. Microchimerism: tolerance vs. sensitization. *Curr Opin Organ Transplant* 2011; **16**: 359-365 [PMID: 21666480 DOI: 10.1097/MOT.0b013e3283484b57]

99 **Bonilla WV**, Geuking MB, Aichele P, Ludewig B, Hengartner H, Zinkernagel RM. Microchimerism maintains deletion of the donor cell-specific CD8+ T cell repertoire. *J Clin Invest* 2006; **116**: 156-162 [PMID: 16395404 DOI: 10.1172/JCI26565]

100 **Burlingham WJ**, Grailer AP, Fechner JH, Kusaka S, Trucco M, Kocova M, Belzer FO, Sollinger HW. Microchimerism linked to cytotoxic T lymphocyte functional unresponsiveness (clonal anergy) in a tolerant renal transplant recipient. *Transplantation* 1995; **59**: 1147-1155 [PMID: 7732562]

101 **Wittnich C**, Belanger MP, Askin N, Boscarino C, Wallen WJ. Lower liver transplant success in females: gender differences in metabolic response to global ischemia. *Transplant Proc* 2004; **36**: 1485-1488 [PMID: 15251365 DOI: 10.1016/j.transproceed.2004.05.055]

102 **Jin B**, Liu CZ, Hu SY, Wang TT, Wang L, Jiang XS, Frezza EE. Influence of estrogen and androgen on the outcome of liver transplantation. *Hepatogastroenterology* 2008; **55**: 207-211 [PMID: 18507108]

103 **Vilatoba M**, Eckstein C, Bilbao G, Frennete L, Eckhoff DE, Contreras JL. 17beta-estradiol differentially activates mitogen-activated protein-kinases and improves survival following reperfusion injury of reduced-size liver in mice. *Transplant Proc* 2005; **37**: 399-403 [PMID: 15808658 DOI: 10.1016/j.transproceed.2004.12.053]

104 **Shen SQ**, Zhang Y, Xiong CL. The protective effects of 17beta-estradiol on hepatic ischemia-reperfusion injury in rat model, associated with regulation of heat-shock protein expression. *J Surg Res* 2007; **140**: 67-76 [PMID: 17336333 DOI: 10.1016/j.jss.2006.10.022]

105 **Harada H**, Pavlick KP, Hines IN, Hoffman JM, Bharwani S, Gray L, Wolf RE, Grisham MB. Selected contribution: Effects of gender on reduced-size liver ischemia and reperfusion injury. *J Appl Physiol (1985)* 2001; **91**: 2816-2822 [PMID: 11717250]

106 **Eckhoff DE**, Bilbao G, Frenette L, Thompson JA, Contreras JL. 17-Beta-estradiol protects the liver against warm ischemia/reperfusion injury and is associated with increased serum nitric oxide and decreased tumor necrosis factor-alpha. *Surgery* 2002; **132**: 302-309 [PMID: 12219027]

107 **Soric S**, Belanger MP, Askin N, Wittnich C. Impact of female sex hormones on liver tissue lactic acidosis during ischemia. *Transplantation* 2007; **84**: 763-770 [PMID: 17893610 DOI: 10.1097/01.tp.0000280542.61123.ec]

108 **Buis CI**, Verdonk RC, Van der Jagt EJ, van der Hilst CS, Slooff MJ, Haagsma EB, Porte RJ. Nonanastomotic biliary strictures after liver transplantation, part 1: Radiological features and risk factors for early vs. late presentation. *Liver Transpl* 2007; **13**: 708-718 [PMID: 17457932 DOI: 10.1002/lt.21166]

109 **Schoening WN**, Buescher N, Rademacher S, Andreou A, Kuehn S, Neuhaus R, Guckelberger O, Puhl G, Seehofer D, Neuhaus P. Twenty-year longitudinal follow-up after orthotopic liver transplantation: a single-center experience of 313 consecutive cases. *Am J Transplant* 2013; **13**: 2384-2394 [PMID: 23915357 DOI: 10.1111/ajt.12384]

110 **Yadav AD**, Chang YH, Aqel BA, Byrne TJ, Chakkera HA, Douglas DD, Mulligan DC, Rakela J, Vargas HE, Carey EJ. New Onset Diabetes Mellitus in Living Donor versus Deceased Donor Liver Transplant Recipients: Analysis of the UNOS/OPTN Database. *J Transplant* 2013; **2013**: 269096 [PMID: 24205434 DOI: 10.1155/2013/269096]

111 **Polotsky HN**, Polotsky AJ. Metabolic implications of menopause. *Semin Reprod Med* 2010; **28**: 426-434 [PMID: 20865657 DOI: 10.1055/s-0030-1262902]

112 **Burra P**, Senzolo M, Masier A, Prestele H, Jones R, Samuel D, Villamil F. Factors influencing renal function after liver transplantation. Results from the MOST, an international observational study. *Dig Liver Dis* 2009; **41**: 350-356 [PMID: 19046932 DOI: 10.1016/j.dld.2008.09.018]

113 **Campsen J**, Zimmerman M, Trotter J, Hong J, Freise C, Brown RS, Cameron A, Ghobrial M, Kam I, Busuttil R, Saab S, Holt C, Emond JC, Stiles JB, Lukose T, Chang MS, Klintmalm G. Multicenter review of liver transplant for hepatitis B-related liver disease: disparities in gender and ethnicity. *Clin Transplant* 2013; **27**: 829-837 [PMID: 24033475 DOI: 10.1111/ctr.12224]

114 **Ponziani FR**, Viganò R, Iemmolo RM, Donato MF, Rendina M, Toniutto P, Pasulo L, Morelli MC, Burra P, Miglioresi L, Merli M, Di Paolo D, Fagiuoli S, Gasbarrini A, Pompili M, Belli L, Gerunda GE, Marino M, Montalti R, Di Benedetto F, De Ruvo N, Rigamonti C, Colombo M, Rossi G, Di Leo A, Lupo L, Memeo V, Bringiotti R, Zappimbulso M, Bitetto D, Vero V, Colpani M, Fornasiere E, Pinna AD, Morelli MC, Bertuzzo V, De Martin E, Senzolo M, Ettorre GM, Visco-Comandini U, Antonucci G, Angelico M, Tisone G, Giannelli V, Giusto M. Long-term maintenance of sustained virological response in liver transplant recipients treated for recurrent hepatitis C. *Dig Liver Dis* 2014; **46**: 440-445 [PMID: 24635906 DOI: 10.1016/j.dld.2014.01.157]

115 **De Martin E**, Senzolo M, Gambato M, Germani G, Vitale A, Russo FR, Burra P. Fibrosis progression and the pros and cons of antiviral therapy for hepatitis C virus recurrence after liver transplantation: a review. *Transplant Proc* 2010; **42**: 2223-2225 [PMID: 20692449 DOI: 10.1016/j.transproceed.2010.05.035]

116 **De Martin E**, Senzolo M, Boninsegna S, Guido M, Masier A, Germani G, Tomat S, Brolese A, Neri D, Cillo U, Gambato M, Russo FP, Farinati F, Burra P. HCV histological recurrence and survival following liver transplantation in patients with and without hepatocellular carcinoma. *Transplant Proc* 2008; **40**: 1974-1975 [PMID: 18675104 DOI: 10.1016/j. transproceed.2008.05.040]

117 **Lai JC**, Verna EC, Brown RS, O'Leary JG, Trotter JF, Forman LM, Duman JD, Foster RG, Stravitz RT, Terrault NA. Hepatitis C virus-infected women have a higher risk of advanced fibrosis and graft loss after liver transplantation than men. *Hepatology* 2011; **54**: 418-424 [PMID: 21538434 DOI: 10.1002/hep.24390]

118 **Belli LS**, Burroughs AK, Burra P, Alberti AB, Samonakis D, Cammà C, De Carlis L, Minola E, Quaglia A, Zavaglia C, Vangeli M, Patch D, Dhillon A, Cillo U, Guido M, Fagiuoli S, Giacomoni A, Slim OA, Airoldi A, Boninsegna S, Davidson BR, Rolles K, Pinzello G. Liver transplantation for HCV cirrhosis: improved survival in recent years and increased severity of recurrent disease in female recipients: results of a long term retrospective study. *Liver Transpl* 2007; **13**: 733-740 [PMID: 17370330 DOI: 10.1002/lt.21093]

119 **Shimizu I**, Mizobuchi Y, Yasuda M, Shiba M, Ma YR, Horie T, Liu F, Ito S. Inhibitory effect of oestradiol on activation of rat hepatic stellate cells in vivo and in vitro. *Gut* 1999; **44**: 127-136 [PMID: 9862839]

120 **Yasuda M**, Shimizu I, Shiba M, Ito S. Suppressive effects of estradiol on dimethylnitrosamine-induced fibrosis of the liver in rats. *Hepatology* 1999; **29**: 719-727 [PMID: 10051473 DOI: 10.1002/hep.510290307]

121 **Poynard T**, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. *Lancet* 1997; **349**: 825-832 [PMID: 9121257]

122 **Deuffic-Burban S**, Poynard T, Valleron AJ. Quantification of fibrosis progression in patients with chronic hepatitis C using a Markov model. *J Viral Hepat* 2002; **9**: 114-122 [PMID: 11876793]

123 **Codes L**, Asselah T, Cazals-Hatem D, Tubach F, Vidaud D, Paraná R, Bedossa P, Valla D, Marcellin P. Liver fibrosis in women with chronic hepatitis C: evidence for the negative role of the menopause and steatosis and the potential benefit of hormone replacement therapy. *Gut* 2007; **56**: 390-395 [PMID: 17005762 DOI: 10.1136/gut.2006.101931]

124 **Burra P**. Liver abnormalities and endocrine diseases. *Best Pract Res Clin Gastroenterol* 2013; **27**: 553-563 [PMID: 24090942 DOI: 10.1016/j.bpg.2013.06.014]

125 **Giannelli V**, Giusto M, Farcomeni A, Ponziani FR, Pompili M, Viganò R, Iemmolo RM, Donato MF, Rendina M, Toniutto P, Pasulo L, Morelli MC, De Martin E, Miglioresi L, Di Paolo D, Fagiuoli S, Merli M. Treatment of hepatitis C recurrence is less successful in female than in male liver transplant recipients. *Transpl Int* 2012; **25**: 448-454 [PMID: 22353419 DOI: 10.1111/j.1432-2277.2012.01440.x]

126 Abstracts of the 2011 Joint International Congress of ILTS (International Liver Transplantation Society), ELITA (European Liver and Intestine Transplant Association), and LICAGE (Liver Intensive Care Group of Europe). June 22-25, 2011. Valencia, Spain. *Liver Transpl* 2011; **17 Suppl 1**: S79-324 [PMID: 21618695]

127 **Ebeling PR**. Approach to the patient with transplantation-related bone loss. *J Clin Endocrinol Metab* 2009; **94**: 1483-1490 [PMID: 19420272 DOI: 10.1210/jc.2009-0205]

128 **Kulak CA**, Borba VZ, Kulak J, Custódio MR. Osteoporosis after transplantation. *Curr Osteoporos Rep* 2012; **10**: 48-55 [PMID: 22167576 DOI: 10.1007/s11914-011-0083-y]

129 **Melton LJ**. How many women have osteoporosis now? *J Bone Miner Res* 1995; **10**: 175-177 [PMID: 7754796 DOI: 10.1002/jbmr.5650100202]

130 **Defranco DJ**, Lian JB, Glowacki J. Differential effects of glucocorticoid on recruitment and activity of osteoclasts induced by normal and osteocalcin-deficient bone implanted in rats. *Endocrinology* 1992; **131**: 114-121 [PMID: 1611989 DOI: 10.1210/endo.131.1.1611989]

131 **Canalis E**, Delany AM. Mechanisms of glucocorticoid action in bone. *Ann N Y Acad Sci* 2002; **966**: 73-81 [PMID: 12114261]

132 **Epstein S**. Post-transplantation bone disease: the role of immunosuppressive agents and the skeleton. *J Bone Miner Res* 1996; **11**: 1-7 [PMID: 8770690 DOI: 10.1002/jbmr.5650110102]

133 **Goffin E**, Devogelaer JP, Depresseux G, Squifflet JP, Pirson Y. Osteoporosis after organ transplantation. *Lancet* 2001; **357**: 1623 [PMID: 11386322]

134 **Monegal A**, Navasa M, Guañabens N, Peris P, Pons F, Martínez de Osaba MJ, Rimola A, Rodés J, Muñoz-Gómez J. Bone mass and mineral metabolism in liver transplant patients treated with FK506 or cyclosporine A. *Calcif Tissue Int* 2001; **68**: 83-86 [PMID: 11310351]

135 **Baccaro LF**, Boin IF, Pedro AO, Costa-Paiva L, Leal AL, Ramos CD, Pinto-Neto AM. Decrease in bone mass in women after liver transplantation: associated factors. *Transplant Proc* 2011; **43**: 1351-1356 [PMID: 21620127 DOI: 10.1016/j.transproceed.2011.02.027]

136 **Baccarani U**, Piselli P, Serraino D, Adani GL, Lorenzin D, Gambato M, Buda A, Zanus G, Vitale A, De Paoli A, Cimaglia C, Bresadola V, Toniutto P, Risaliti A, Cillo U, Bresadola F, Burra P. Comparison of de novo tumours after liver transplantation with incidence rates from Italian cancer registries. *Dig Liver Dis* 2010; **42**: 55-60 [PMID: 19497797 DOI: 10.1016/j.dld.2009.04.017]

137 **Baccarani U**, Adani GL, Serraino D, Lorenzin D, Gambato M, Buda A, Zanus G, Vitale A, Piselli P, De Paoli A, Bresadola V, Risaliti A, Toniutto P, Cillo U, Bresadola F, Burra P. De novo tumors are a major cause of late mortality after orthotopic liver transplantation. *Transplant Proc* 2009; **41**: 1303-1305 [PMID: 19460546 DOI: 10.1016/j.transproceed.2009.03.079]

138 **Serraino D**, Piselli P, Busnach G, Burra P, Citterio F, Arbustini E, Baccarani U, De Juli E, Pozzetto U, Bellelli S, Polesel J, Pradier C, Dal Maso L, Angeletti C, Carrieri MP, Rezza G, Franceschi S. Risk of cancer following immunosuppression in organ transplant recipients and in HIV-positive individuals in southern Europe. *Eur J Cancer* 2007; **43**: 2117-2123 [PMID: 17764927 DOI: 10.1016/j.ejca.2007.07.015]

139 **Ettorre GM**, Piselli P, Galatioto L, Rendina M, Nudo F, Sforza D, Miglioresi L, Fantola G, Cimaglia C, Vennarecci G, Vizzini GB, Di Leo A, Rossi M, Tisone G, Zamboni F, Santoro R, Agresta A, Puro V, Serraino D. De novo malignancies following liver transplantation: results from a multicentric study in central and southern Italy, 1990-2008. *Transplant Proc* 2013; **45**: 2729-2732 [PMID: 24034034 DOI: 10.1016/j.transproceed.2013.07.050]

140 **Chatrath H**, Berman K, Vuppalanchi R, Slaven J, Kwo P, Tector AJ, Chalasani N, Ghabril M. De novo malignancy post-liver transplantation: a single center, population controlled study. *Clin Transplant* 2013; **27**: 582-590 [PMID: 23808800 DOI: 10.1111/ctr.12171]

141 **Heneghan MA**, Selzner M, Yoshida EM, Mullhaupt B. Pregnancy and sexual function in liver transplantation. *J Hepatol* 2008; **49**: 507-519 [PMID: 18715668 DOI: 10.1016/j.jhep.2008.07.011]

142 **Christopher V**, Al-Chalabi T, Richardson PD, Muiesan P, Rela M, Heaton ND, O'Grady JG, Heneghan MA. Pregnancy outcome after liver transplantation: a single-center experience of 71 pregnancies in 45 recipients. *Liver Transpl* 2006; **12**: 1138-1143 [PMID: 16799943 DOI: 10.1002/lt.20810]

143 **Terrabuio DR**, Abrantes-Lemos CP, Carrilho FJ, Cançado EL. Follow-up of pregnant women with autoimmune hepatitis: the disease behavior along with maternal and fetal outcomes. *J Clin Gastroenterol* 2009; **43**: 350-356 [PMID: 19077726 DOI: 10.1097/MCG.0b013e318176b8c5]

144 **Penney GC**, Mair G, Pearson DW. Outcomes of pregnancies in women with type 1 diabetes in Scotland: a national population-based study. *BJOG* 2003; **110**: 315-318 [PMID: 12628275]

145 **Schramm C**, Herkel J, Beuers U, Kanzler S, Galle PR, Lohse AW. Pregnancy in autoimmune hepatitis: outcome and risk factors. *Am J Gastroenterol* 2006; **101**: 556-560 [PMID: 16464221 DOI: 10.1111/j.1572-0241.2006.00479.x]

146 **Buchel E**, Van Steenbergen W, Nevens F, Fevery J. Improvement of autoimmune hepatitis during pregnancy followed by flare-up after delivery. *Am J Gastroenterol* 2002; **97**: 3160-3165 [PMID: 12492204 DOI: 10.1111/j.1572-0241.2002.07124.x]

147 **Westbrook RH**, Yeoman AD, Kriese S, Heneghan MA. Outcomes of pregnancy in women with autoimmune hepatitis. *J Autoimmun* 2012; **38**: J239-J244 [PMID: 22261501 DOI: 10.1016/j.jaut.2011.12.002]

148 **Park ES**, Villanueva CA, Viers BR, Siref AB, Feloney MP. Assessment of sexual dysfunction and sexually related personal distress in patients who have undergone orthotopic liver transplantation for end-stage liver disease. *J Sex Med* 2011; **8**: 2292-2298 [PMID: 21492399 DOI: 10.1111/j.1743-6109.2011.02264.x]

149 **Burra P**, Germani G, Masier A, De Martin E, Gambato M, Salonia A, Bo P, Vitale A, Cillo U, Russo FP, Senzolo M. Sexual dysfunction in chronic liver disease: is liver transplantation an effective cure? *Transplantation* 2010; **89**: 1425-1429 [PMID: 20463637 DOI: 10.1097/TP.0b013e3181e1f1f6]

150 **Parolin MB**, Rabinovitch I, Urbanetz AA, Scheidemantel C, Cat ML, Coelho JC. Impact of successful liver transplantation on reproductive function and sexuality in women with advanced liver disease. *Transplant Proc* 2004; **36**: 943-944 [PMID: 15194326 DOI: 10.1016/j.transproceed.2004.03.124]

151 **Ho JK**, Ko HH, Schaeffer DF, Erb SR, Wong C, Buczkowski AK, Scudamore CH, Yoshida EM. Sexual health after orthotopic liver transplantation. *Liver Transpl* 2006; **12**: 1478-1484 [PMID: 16741905 DOI: 10.1002/lt.20831]

152 **Cundy TF**, O'Grady JG, Williams R. Recovery of menstruation and pregnancy after liver transplantation. *Gut* 1990; **31**: 337-338 [PMID: 2323601]

153 **Mass K**, Quint EH, Punch MR, Merion RM. Gynecological and reproductive function after liver transplantation. *Transplantation* 1996; **62**: 476-479 [PMID: 8781613]

154 **Jabiry-Zieniewicz Z**, Cyganek A, Luterek K, Bobrowska K, Kamiński P, Ziółkowski J, Zieniewicz K, Krawczyk M. Pregnancy and delivery after liver transplantation. *Transplant Proc* 2005; **37**: 1197-1200 [PMID: 15848667 DOI: 10.1016/j.transproceed.2005.01.011]

155 **Burra P**. Sexual dysfunction after liver transplantation. *Liver Transpl* 2009; **15 Suppl 2**: S50-S56 [PMID: 19876949 DOI: 10.1002/lt.21899]

156 **Jabiry-Zieniewicz Z**, Kaminski P, Bobrowska K, Pietrzak B, Wielgos M, Smoter P, Zieniewicz K, Krawczyk M. Menstrual function in female liver transplant recipients of reproductive age. *Transplant Proc* 2009; **41**: 1735-1739 [PMID: 19545718 DOI: 10.1016/j.transproceed.2009.03.073]

157 **Murthy SK**, Heathcote EJ, Nguyen GC. Impact of cirrhosis and liver transplant on maternal health during labor and delivery. *Clin Gastroenterol Hepatol* 2009; **7**: 1367-172, 1372.e1 [PMID: 19686866 DOI: 10.1016/j.cgh.2009.08.008]

158 **Kim HW**, Seok HJ, Kim TH, Han DJ, Yang WS, Park SK. The experience of pregnancy after renal transplantation: pregnancies even within postoperative 1 year may be tolerable. *Transplantation* 2008; **85**: 1412-1419 [PMID: 18497680 DOI: 10.1097/TP.0b013e318170f8ed]

159 **Gerlei Z**, Wettstein D, Rigó J, Asztalos L, Langer RM. Childbirth after organ transplantation in Hungary. *Transplant Proc* 2011; **43**: 1223-1224 [PMID: 21620095 DOI: 10.1016/j.transproceed.2011.03.087]

160 **Wielgos M**, Szpotanska-Sikorska M, Mazanowska N, Bomba-Opon D, Kociszewska-Najman B, Jabiry-Zieniewicz Z, Cyganek A, Kaminski P, Pietrzak B. Pregnancy risk in female kidney and liver recipients: a retrospective comparative study. *J Matern Fetal Neonatal Med* 2012; **25**: 1090-1095 [PMID: 21919553 DOI: 10.3109/14767058.2011.622010]

161 **Jabiry-Zieniewicz Z**, Szpotanska-Sikorska M, Pietrzak B, Kociszewska-Najman B, Foroncewicz B, Mucha K, Zieniewicz K, Krawczyk M, Wielgos M. Pregnancy outcomes among female recipients after liver transplantation: further experience. *Transplant Proc* 2011; **43**: 3043-3047 [PMID: 21996220 DOI: 10.1016/j.transproceed.2011.08.070]

162 **Deshpande NA**, James NT, Kucirka LM, Boyarsky BJ, Garonzik-Wang JM, Cameron AM, Singer AL, Dagher NN, Segev DL. Pregnancy outcomes of liver transplant recipients: a systematic review and meta-analysis. *Liver Transpl* 2012; **18**: 621-629 [PMID: 22344967 DOI: 10.1002/lt.23416]

163 **Zahn A**, Seubert L, Jünger J, Schellberg D, Weiss KH, Schemmer P, Stremmel W, Sauer P, Gotthardt DN. Factors influencing long-term quality of life and depression in German liver transplant recipients: a single-centre cross-sectional study. *Ann Transplant* 2013; **18**: 327-335 [PMID: 23817439 DOI: 10.12659/AOT.883962]

164 **Bianco T**, Cillo U, Amodio P, Zanus G, Salari A, Neri D, Bombonato G, Schiff S, Baggio G, Ronco C, Brocca A, Soni S, Minazzato L. Gender differences in the quality of life of patients with liver cirrhosis related to hepatitis C after liver transplantation. *Blood Purif* 2013; **36**: 231-236 [PMID: 24496196 DOI: 10.1159/000356362]

**P-Reviewers:** Silva R, Xia VW **S-Editor:** Ji FF **L-Editor: E-Editor:**

**Table 1 Key points**

|  |
| --- |
| Several factors contribute to the inequal access to liver transplantation that penalizes women, including inadequacy of MELD score in accounting for renal dysfunction in females, the limitation of MELD score in reflecting the actual severity of liver disease and associated complications in certain clinical conditions that are more frequent in women, and the centers’ increasing prevalence of policies that favor transplantation for hepatocellular carcinoma, which is more frequent in males.  |
| Different etiologies of liver disease follow a characteristic pattern of gender-related frequency, natural evolution, and response to treatment, partly owing to socioepidemiological factors as well as to phenotypical differences regarding enzymatic activity and hormonal status. |
| Within the female population, a clear difference exists between the pre- and the post-menopausal stages, and after this turning point, the protective effect of estrogens on slowing fibrosis progression, amongst others, is lost, causing an acceleration of hepatic injury, a detrimental response to therapy, and the establishment of a new set of complications associated with altered fat and bone metabolism. |
| Although long-term overall outcomes after liver transplantation are better in women, certain conditions such as renal dysfunction, hepatocellular carcinoma as an indication for transplant and recurrent infection with hepatitis C are associated with worse prognosis in women with respect to men. |
| In spite fertility and sexual activity may be curbed in advanced cirrhosis, there are numerous reports of unaffected pregnancies in this stage, while successful liver transplantation restores fertility and sexual activity in most patients, with pregnancy outcomes which are reportedly better in comparison to those obtained after kidney transplantation. |

MELD: Model for end-stage liver disease.